As of Oct 20
| +0.005 / +0.34%|
The 2 analysts offering 12-month price forecasts for Pluristem Therapeutics Inc have a median target of 3.25, with a high estimate of 3.50 and a low estimate of 3.00. The median estimate represents a +117.39% increase from the last price of 1.50.
The current consensus among 2 polled investment analysts is to Buy stock in Pluristem Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.